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Calgranulins are a family of powerful chemoattractants, which have been implicated as
biomarkers in inflammatory diseases. To determine how different respiratory diseases
affect the expression of calgranulins, we measured the expression of S100A8/A9 and
S100A12 in bronchoalveolar lavage fluid (BALF) of acute respiratory distress syndrome
(ARDS) patients and healthy volunteers by ELISA. Analysis of calgranulin expression
revealed a high level of S100A12 in the lavages of patients suffering from ARDS compared
to controls (po0.001). Based on the hypothesis that the increased expression of S100A12
relative to the S100A8/A9 heterodimer was a characteristic of respiratory diseases with
neutrophilic inflammation, we measured calgranulin expression in BALF of cystic fibrosis
(CF) patients. Despite similarly elevated levels of S100A8/A9, S100A12 was significantly
higher in ARDS compared to CF BALF (po0.001). The differential expression of calgranulins
was unique for inflammatory markers, as an array of cytokines did not differ between CF
and ARDS patients.
Since ARDS is an acute event and CF a chronic inflammation with acute exacerbations, we
compared calgranulin expression in sputum obtained from CF and patients with chronic
obstructive lung disease (COPD). Levels of S100A12 and S100A8/9 were elevated in CF
sputum compared to COPD sputum, but the ratio of S100A12 to S100A8/A9 was similar in
COPD and CF and reflected more closely than seen in healthy controls. The results indicateElsevier Ltd. All rights reserved.
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may provide important insights in the mechanism of respiratory inflammation.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Recent evidence in mammals has implicated calgranulins as
important mediators of neutrophil influx during infec-
tions.1–3 Calgranulins (S100A8, S100A9, and S100A12) are
members of the S100 family of small calcium-binding
proteins4 and are expressed predominantly in the cytosol
of neutrophils and monocytes. Calgranulins exist as homo-
dimers; but S100A8 and S100A9 can also form a heterodimer
(S100A8/A9), which is the predominant form found in the
cytosol and the extracellular space. S100A8, S100A9, and
S100A12 stimulate neutrophil and monocyte chemotaxis,
adhesion to fibrinogen and diapedesis in vitro, as well as
neutrophil migration to inflammatory sites in vivo.3,5–7
Calgranulin expression varies between cell types and
stimuli. For instance, while S100A8 expression is increased
in macrophages following acute LPS stimulation, S100A9
responds to additional stimuli, including peptidoglycans,
expressed by Gram-positive bacteria.2,8 Evidence from
S100A9-deficient mice also indicates that the presence of
S100A9 protein is required for the translation of S100A8
mRNA, while S100A12, which is only expressed in humans
but absent in mice, is known to be induced by IL-6.9 Acute
respiratory distress syndrome (ARDS) is associated with
elevated IL-6 levels10 and conceivably this IL-6 response
could enhance the expression of S100A12 during the
inflammatory cascade that occurs in the lung following an
acute injury.
ARDS is a frequent complication in trauma patients and
constitutes one of the leading causes of mortality in
critically ill patients.11–13 ARDS is characterized by a
heightened inflammatory response secondary to severe lung
injury.14–16 The severity and outcome of ARDS is thought to
be determined by the balance of activated neutrophils and
the secretion of cytokines and chemokines. Reports suggest
that the neutrophil influx in ARDS may be secondary to the
lung injury rather than the cause of it17,18; but neutrophils
contribute actively to the destruction of the lung. Under-
standing the molecular basis that regulates neutrophil
activation and influx into the airways may therefore be
important in limiting the lung injury through these inflam-
matory mediators. To determine how calgranulin expression
is altered during ARDS, we analyzed calgranulin expression
in patients suffering from acute and chronic pulmonary
diseases.
Calgranulins have also been described in the pathogenesis
of cystic fibrosis (CF), a disease characterized by excessive
neutrophil driven inflammation in the lung and by chronic
infection. The calgranulin heterodimer S100A8/A9 has been
reported as the CF antigen, which was found to be up-
regulated in the serum and sputum of CF patients.19 More
recently, S100A12 was also found to be elevated in the
serum and sputum of CF patients during acute exacerba-
tions,20 which might implicate S100A12 in acute pulmonary
disease.Since S100A8 and S100A9 form a heterodimer, but are
independent of S100A12, we hypothesized that the ratio of
S100A12 to S100A8/A9 could differ between acute and
chronic respiratory infections. S100A12 expression is of
particular interest in acute respiratory diseases as it is
induced by IL-6, which is one of the cytokines implicated in
the pathogenesis of ARDS.10 Since mice lack functional
S100A12, we compared S100A12 expression with S100A8/A9
in patients suffering from acute and chronic respiratory
diseases.Materials and methods
Patient recruitment and characteristics
Patients admitted to the trauma Intensive Care Unit (ICU)
were eligible for inclusion in this study if ARDS, defined as
PaO2/FIO2 ratio o200, developed during their stay in the
ICU. Additional ARDS patients were identified from the
pulmonary/critical care unit using the American-European
Consensus Conference definition.21 All patients underwent
clinically indicated bronchoscopy within the first 4 days of
meeting ARDS criteria.
BAL fluid was obtained from CF patients undergoing
clinically indicated bronchoscopy for increased respiratory
symptoms suggestive of new infection and who were unable
to produce sputum. Diagnosis of CF had been confirmed
according to consensus criteria, including a positive sweat
test.22 Two of the bronchoalveolar lavage fluid (BALF)
samples from CF patients were not infected; the remaining
BALF had infections with various Gram-positive and Gram-
negative organisms, including two children with Pseudomo-
nas aeruginosa infections. Since a subsequent comparison
with chronic obstructive lung disease (COPD) patients was
necessary and bronchoscopy is risky and rarely indicated for
clinical reasons in COPD, we also collected sputum from
clinically stable patients with CF at completion of intrave-
nous antibiotic treatment.
COPD patients with mild to moderate disease severity, as
defined by Global Institute for Chronic Obstructive Lung
Disease (GOLD score p2)23 were recruited to undergo
sputum induction. Five of the patients continued to be
active smokers. One patient was on oral corticosteroid
therapy (prednisone), while the other patients were on
combination of medicines including short and long acting
beta-agonist therapy. All patients were clinically stable and
had not experienced any exacerbations of their COPD within
the preceding three months. All COPD patients were pre-
treated with beta-agonist (albuterol) prior to sputum
induction.
Healthy adult controls were recruited for the collection of
BALF as part of a GCRC-sponsored protocol on lung
inflammation and injury in asthma and ARDS. Healthy
controls for sputum induction were recruited as part of a
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the Institutional Review Board, was obtained from all
patients and healthy controls. Patient demographics are
indicated in Table 1.
BALF and sputum processing
Bronchoscopy on medical ICU patients was performed in
either the lingula or right middle lobe using four 50ml
aliquots of sterile saline. For comparison, BALF from healthy
volunteers was obtained as described.25 Bronchoscopy and
bronchoalveolar lavage on trauma patients was performed
in the affected area of the lung using three 50ml aliquots of
sterile saline. Bronchoscopy in children with CF was
performed under sedation or general anesthesia and BAL
was performed by instilling two to three aliquots of 1ml/kg
(max. 30 cm3) sterile saline and immediately aspirating the
fluid through the bronchoscope.26 The BAL was performed in
the most affected segment selected by clinical findings on
X-ray or bronchoscopy. The total BALF was centrifuged
(200 g for 10min) to isolate the cells. The cell free
supernatants were stored at 20 1C for ELISA. Induced
sputum was performed and processed as previously de-
scribed.27
Measurement of calgranulins in bronchoalveolar
lavage
ELISA assays for calgranulin expression in the lung lavage
were done as previously described.28 Briefly, for the ELISA
measurement of S100A8 and S100A9, Costar High Binding 96-
well plates (Corning, NY) were coated overnight at 4 1C with
100 ml/well purified rabbit IgG against S100A8 or S100A9
diluted to a concentration of 1 mg/ml in 0.1M carbonate
buffer, pH 9.6. The wells were blocked with PBS/0.1% Tween
20/2% BSA (150 ml/well) for 30min at room temperature.
The samples and standards (100 ml) were added and
incubated for 45min at room temperature. The plates were
washed three times with PBS/0.1% Tween 20, and were
incubated with rat IgG (100 ml/well) against S100A8 or
S100A9 diluted in PBS/0.1% Tween 20/2% BSA (1/10,000) for
45min at room temperature. The plates were then washed
three times in PBS/0.1% Tween 20. To reveal the immune
complex, peroxidase-conjugated goat anti-rat IgG (H+L)
(minimum cross-reaction to rabbit serum proteins)
(100 ml/well), at a dilution of 1/10,000, was added and
incubated 45min at room temperature. The plates were
washed three times and 100 ml/well TMB-S substrate was
added according to the manufacturer’s instructions. The
o.d.s were read at 500 nm. The lower limit of quantification
was determined as 4 ng/ml for both S100A8 and S100A9.
For the ELISA assays to measure the S100A8/A9 hetero-
dimer, 96-well plates were coated overnight at 4 1C with
purified anti-S100A9 rabbit IgG (ml/100 well) diluted 1 mg/ml
in 0.1M carbonate buffer, pH 9.6. The wells were blocked
with PBS/0.1% Tween 20/2% BSA (150 ml/well) for 30min at
room temperature. The samples and standards (100 ml) were
added and incubated for 45min at room temperature. The
plates were washed three times with PBS/0.1% Tween 20
then incubated with 100 ml/well anti-S100A8 rat IgG diluted
in PBS/0.1% Tween 20/2% BSA (1/10,000) for 45min at roomtemperature. The plates were next washed three times in
PBS/0.1% Tween 20 and incubated with 100 ml/well perox-
idase-conjugated goat anti-rat IgG at a dilution of 1/10,000
for 45min at room temperature. After three washes,
100 ml/well TMB-S substrate were added according to the
manufacturer’s instructions. The optical densities (ODs)
were read on a plate reader at 500 nm. The lower limit of
quantification of this assay was determined as 10 ng/ml. All
three ELISAs were tested using excess amounts (100 times)
of S100A8, S100A9, or S100A8/A9 proteins and were shown
to be specific under the conditions reported here. In
addition, spiking studies revealed that no inhibitors in the
BALF and sputum interfered with the ELISA readouts.
Statistics
Sputum and bronchoalveolar lavage measurements for S100
proteins were normalized against total protein content in
the samples as indicated. Calgranulin concentration in BAL
fluid is reported as median and range for the patient groups.
Nonparametric analysis (Mann–Whitney test) was used to
compare the calgranulin expression between the test
groups, with significance defined as po0.05. Data were log
transformed only for graphical presentation.
Results
S100A12 levels are elevated in the BALF of ARDS
patients compared to CF patients
The heterodimer S100A8/A9 has been reported to mediate
the neutrophil influx following an acute LPS stimulation29
and is also up-regulated in the sputum of CF patients, who
have neutrophil dominated lung inflammation.19 When we
compared S100A8/A9 levels in CF and ARDS patients, we
found similar levels of calgranulin heterodimer normalized
to total BAL protein in both groups of patients (Figure 1,
closed symbols) (Table 1).
By contrast, the expression of S100A12 protein, which is
associated with acute exacerbations in CF patients,20 was
significantly higher in BALF of ARDS patients compared to
that measured in BALF of CF patients (Figure 1, open
symbols) (median 98.2, range 0.9–682) versus CF (29.7,
range 0.96–212.9) (p ¼ 0.0004). S100 proteins were also
measured in BAL obtained from healthy control individuals.
Comparison of S100, non-normalized to total BAL protein,
showed that both patient groups had significantly higher
levels of S100 A8/A9 and of S100A12 than healthy controls,
who had a median (range) 19.4 (9–77) ng/ml and 1819
(236–17,853) ng/ml (po0.001), respectively. The data for
the comparison of the raw measurements is shown in the
online supplement.
As production and likely also the function of S100A12
differs from that of the S100A8/A9 heterodimer, we
compared the ratios of these two proteins.30 The ratio of
S100A12 to S100A8/A9 in the BAL of ARDS patients was not
significantly different from healthy controls (p ¼ 0.112).
Compared to ARDS patients and healthy controls, the ratio
S100A12 to S100A8/A9 was significantly lower in CF patients
(po0.001) (Figure 2). Thus, the profile of calgranulin
expression differs significantly between CF and ARDS
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elevation of S100A12 and S100A8/A9. However, when
stratifying patients with ARDS by etiology (six patients with
direct versus seven patients with indirect lung injury), we
observed no difference in either S100A12 or S100A8/A9 or
their ratio to each other (data not shown).
To determine whether the difference observed in the
calgranulin ratio between CF and ARDS was specific for
calgranulins or shared by other inflammatory markers, the
expression of multiple inflammatory mediators was deter-
mined. We measured an array of cytokines expressed in
BALF samples during ARDS and CF. These cytokines and the
S100 proteins were corrected for total protein in BALF. The
following cytokines were analyzed: RANTES, IL-6, IL-8, IP-
10, TNF-a, and ICAM. With the exception of IL-8, which was
significantly higher in CF (p ¼ 0.005), these cytokines were
expressed at similar levels in the BAL fluid of ARDS and CF
patients (data not shown). The difference in the ratio of
S100A8/A9 to S100A12 observed in CF and ARDS patients is
therefore unique to calgranulins and not shared by other
inflammatory mediators.
Sputum calgranulin expression in chronic
respiratory diseases
ARDS and CF exacerbations are acute inflammatory diseases,
in which neutrophils are thought to contribute significantly
to inflammation. To assess if the calgranulin profile differedTable 1 Patient demographics.
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Figure 1 S100A8/A9 and S100A12 expression in the BALF.
S100A12 (open symbols) and S100A8/A9 (closed symbols) were
measured in the BALF of ARDS patients and CF patients. Results
are presented in log-scale, corrected for total protein with the
median values for each subject group indicated.in chronic and acute lung inflammation, we compared stable
CF to stable COPD patients. For ethical reasons, we did not
perform bronchoscopic lavages, but used sputum collected
from COPD and CF patients. Our control samples were
induced sputa obtained form healthy controls.
We measured calgranulin expression in the sputum of CF
patients after a course of intravenous antibiotics to ensure
that the lung inflammation was stabilized and reflected
better the chronic inflammation of stable COPD. For the raw
data, levels of S100A8/A9 were similar in COPD and healthy
controls ((median, range) 581 (116–4648)) ng/ml and (668
(448–16,122) ng/ml, respectively). By contrast, they were
significantly elevated in the sputum of CF patients 15,155
(5996–20,428) ng/ml) (po0.001) (Figure 3). Similarly,
S100A12 expression in the sputum of CF patients
was significantly elevated (po0.001) (median 12,473
(4047–20,993) ng/ml) compared to the COPD patients (172
(28–4693) ng/ml) and the healthy control group 31
(8–1158) ng/ml). We also normalized S100 proteins to total
protein in sputum from CF patients and therefore total
protein was only measured in four samples. Normalization of
the calgranulin levels to total protein content revealed a
similar pattern in COPD and healthy subjects as in the raw
measurements. Normalization was difficult for CF patients
as we had insufficient sputum to measure protein in four
samples, and protein concentrations were at the lower limit
of detection in three of the remaining four samples. When
we accounted for the dilution, these values were in the
detectable range of the assay and we used these to
normalize the S100 protein measurements. In these samples
both S100A8/A9 heterodimer and S100A12 were much higherALF CF sputum COPD sputum Controls sputum
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Figure 2 Ratio of calgranulin expression in the BALF. The
relative expression ratio of S100A12 to S100A8/A9 was
determined in the BALF of ARDS patients, CF patients, and
healthy volunteers. Results are presented on log-scale, with the
median values for each subject group indicated.
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Figure 3 S100A8/A9 and S100A12 expression in the sputum.
S100A12 (open symbols) and S100A8/A9 (closed symbols) were
measured in the sputum of COPD patients and healthy controls.
Results are presented in log-scale, corrected for total protein
with the median values for each subject group indicated.
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Figure 4 Ratio of calgranulin expression in the sputum. The
ratio of S100A12 to S100A8/A9 was determined in the sputum of
COPD patients, CF patients and healthy volunteers. Results are
presented in log-scale, with the median values for each subject
group indicated.
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normalized data seen in the raw S100 protein measurements
(figure available as online supplement).
The ratio of S100A12 to S100A8/A9 was similar in CF and
COPD sputum with stable disease and tended to be higher
than in healthy controls, indicating that S100A8/A9 and
S100A12 increase in chronic lung inflammation with only a
mild predominance of the S100A8/A9 complex (Figure 4).
This is in contrast to the difference in the ratio of S100A8/A9
to S100A12 between CF patients and healthy controls or
ARDS patients; in latter two sample groups S100A12
expression predominates. It is conceivable that the change
in ratio is related to the acute onset of ARDS and other
underlying mechanisms of inflammation.
We also measured an array of cytokines expressed in
sputum samples during COPD, CF, and normal controls. The
following cytokines were analyzed: RANTES, IL-6, IL-8, IP-
10, TNF-a, and ICAM. There was no difference in cytokine
concentrations when normalized to total protein in COPDversus CF patients but the number of samples available for
this analysis was low (data not shown). Interestingly, only
IL-10 was significantly different between COPD and control
patients, with higher values in normal controls.Discussion
The development of ARDS is a serious and common
complication in sepsis patients and trauma patients. The
diagnosis of ARDS in critically ill patients is linked to
severely impaired lung function and increased mortality.
ARDS is characterized by the increased secretion of
cytokines in the airways and intense influx of neutrophils
in the lung. Previous research has related differences in
neutrophil activation to outcome in acute lung injury,31
suggesting that factors regulating the neutrophil influx could
be predictors of outcome. The calgranulin heterodimer
S100A8/A9 has potent chemoattractant capabilities and its
expression is required to mediate the influx of neutrophils
following an acute stimulation with endotoxin in mice.29 As
S100A12 is not expressed in mice and to address how the
expression of calgranulins differs in acute and chronic
human lung disease,30 we investigated the possible role of
calgranulins S100A8/A9 and S100A12 in the acute inflamma-
tory response of ARDS. Expression levels of S100A12 and
S100A8/A9 levels in ARDS patients were not dependent on
whether the patients suffered a direct or indirect injury,
implying that calgranulin expression may not be related to
the severity of ARDS or the risk of mortality both of which
differ based on the injury type.32–35
Calgranulin expression, in particular the elevated levels
of S100A12, however, could be an underlying mechanism for
augmenting the inflammatory response associated with
acute pulmonary infection. Recent studies found elevated
S100A12 levels in the BALF of CF patients during acute
exacerbations. These studies reported levels of up to
11,000 ng/ml,20 similar to the average S100A12 expression
detected in this study and much lower than the level of
S100A12 detected in ARDS patients.
A possible limitation in our study is the comparison of
BALF obtained from pediatric patients with CF versus adults
with ARDS, reflecting the main groups of patients affected
with these diseases. Adults with CF generally can produce
sputum and are sicker than children and thus BAL is not
indicated and could be dangerous for study purposes. On the
other hand, underlying etiologies and definition of ARDS is
even more heterogeneous in pediatric patients.36 The age
and size difference in these groups may affect BAL fluid
volumes and concentration as smaller volumes for BALF are
used in children than adults. We elected not to use
normalization to urea, as concentration of urea in BALF
can be affected by underlying disease and dwell time of the
lavage fluid, especially in children.37,38 More importantly,
we also measured the ratio of S100A8/A9 to S100A12, which
is not affected by dilution, and this ratio is decreased in CF
compared to ARDS.
The different pattern in the expression of an inflamma-
tory marker between CF and ARDS patients is unique to
calgranulins, since a panel of cytokines measured in the
study show similar expression levels in both diseases when
normalized to total protein. This finding supports the notion
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relate to differences in the mechanism of inflammation.
Since CF is characterized by chronic neutrophil dominated
inflammation,39,40 the increased expression of S100A12 in
ARDS suggests that S100A12 could be more important in the
onset of neutrophil influx and is therefore less elevated in
chronic inflammation. Another possibility is the difference
between the systemic inflammation in ARDS whereas the
inflammation in CF is mostly compartmentalized to the lung.
Elevated levels of S100A12 have also been described in
Kawasaki syndrome41 and rheumatoid arthritis,42 two
diseases associated with systemic inflammation. One could
thus speculate that the increased concentration of S100A12
seen in ARDS is linked to the systemic inflammation, e.g. IL-6
and subsequent higher expression in subepithelial cells with
diffusion into the alveolar space.
Our comparison of calgranulin expression in the sputum of
CF and COPD patients underscores the conclusion that the
elevated levels of S100A12 are associated with acute
inflammation. We compared calgranulin expression in CF
with COPD patients who, despite a different underlying
pathogenesis, share the chronic inflammation seen in CF
patients. Both, COPD and CF patients, showed higher levels
of S100A8/A9 expression than S100A12, indicating that
S100A12 is associated with an acute infection, while an
underlying chronic infection will primarily be mediated by
S100A8/A9. In support of this conclusion, healthy controls
show low levels of S100A12 in their sputum, while the
sputum of CF patients at admission showed increased levels
of S100A12 compared to CF sputum at discharge (data not
shown). This is consistent with findings of Foell et al.20 who
showed increase of S100A12 in CF with exacerbations, which
subsequently declined with therapy.
In summary, calgranulins are important markers of
neutrophil dominated infections. However, our data of
significantly elevated S100A12 in ARDS compared to healthy
subjects and increased levels of S100A12 in exacerbations of
chronic lung diseases point towards differential regulation
of S100A12 versus S100A8/A9 in acute versus chronic
inflammation. Our findings contribute to the growing
evidence of increased expression of S100A12 in acute
inflammatory diseases, and contrary to CF or rheumatoid
arthritis significant elevation occurs acutely in previously
healthy persons.Acknowledgments
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